Revolutionizing Care: NeuroQure’s Groundbreaking Path to Treating Genetic Intellectual Disabilities
06 Novembre 2023 - 6:00PM
NeuroQure has embarked on a transformative journey aimed at
revolutionizing the treatment landscape for Fragile X Syndrome and
Autism Spectrum Disorder (ASD). With an unwavering commitment to
addressing the monogenic origins of these conditions, NeuroQure,
founded by businessman Dave Justus and renowned geneticist Dr. Jay
Gargus, MD, Ph.D., is pioneering a path toward curative treatments.
Fragile X and Autism collectively impact over
seven million individuals in the United States and Europe. Despite
this staggering number, there are currently no federally approved
treatments targeting the genetic roots of these disorders.
NeuroQure stands at the forefront of change, channeling the
expertise of Justus, a dedicated entrepreneur, and Dr. Gargus, a
distinguished geneticist. Their collaboration, built on a
decade-long friendship and cultivated through joint efforts at
Friends for Fragile X, a 501(c)(3) non-profit organization, has
given rise to a vision that seeks to transform lives.
Justus, motivated by his role as a father to a
son affected by Fragile X, brings over 20 years of professional
experience in building venture- and private equity-backed
businesses. Dr. Gargus is a highly respected, world-renowned
geneticist who has dedicated his career to advancing scientific
research of neurological disorders. Dr. Gargus was most recently
the Founding Director of UCI’s Center for Autism Research and
Translation where he led a group of over 60 UC Irvine faculty,
resulting in groundbreaking discoveries in Fragile X and
Autism.
NeuroQure is quickly making advances, beginning
with the formation of an all-star advisory board, including Dr. Uta
Francke, one of the foremost experts in neurogenetics, former
Senior Medical Director of 23andMe, professor Emeritus of
Pediatrics and Medical Genetics at Standford University and known
for her ground-breaking accomplishments pioneering chromosomal maps
and gene mapping and for discovering and defining the function of
the neurodevelopmental genes and underlying mutations responsible
for Prader-Willi, Williams-Beuren, and Rett syndromes; Dr. Pauline
Filipek, an autism expert and the past Chair of the American
Academy of Neurology Society Committee to develop Practice
Parameters for ASD and the lead author of the ASD Practice
Parameters; Albert “Bert” Zimmerli, a healthcare industry expert,
recently retired after 20 years as the Executive Vice President and
Chief Financial Officer of Intermountain Health, a fully integrated
$14+ billion health system, and continues to serve on the boards of
Select Health and Intermountain Foundation, and serves as Board
Chairman for Intermountain Health Ventures, LLC, and Culmination
Bio, Inc.; and Dan Dearen, an FDA trial and monetization expert who
most recently served as the President and Chief Financial Officer
of Axonics Modulation Technologies, Inc. (Nasdaq: AXNX), a publicly
traded medical technology company with sales of over $273 million
in 2022, and serves on the board of JenaValve Technology, Inc.
The goal of developing gene therapy to treat intellectual
disabilities fuels both Justus and Dr. Gargus. “Our pursuit is not
just scientific; it’s deeply personal. We envision a future where
intellectual disabilities are not barriers but challenges we can
overcome,” said Justus. “NeuroQure’s mission is not merely
scientific advancement; it’s a beacon of hope for individuals and
families affected by these conditions.”
About NeuroQure: NeuroQure is dedicated to
transforming the lives of those impacted by intellectual
disabilities through genomic innovations that deliver curative
medicines. Founded by businessman David Justus and Dr. John Jay
Gargus, MD, Ph.D., the company is applying a passionate and
disciplined focus to advancing gene therapy for genetically defined
neurocognitive disorders, beginning with Fragile X and Autism. By
merging cutting-edge6+ genomics with foundational research,
NeuroQure aims to expedite the development of groundbreaking
treatments. For more information, visit: www.neuroqure.com.
MEDIA CONTACTEcho Media
Groupkim@echomediateam.com 714-573-0899 ext. 222
Grafico Azioni Axonics (NASDAQ:AXNX)
Storico
Da Apr 2024 a Mag 2024
Grafico Azioni Axonics (NASDAQ:AXNX)
Storico
Da Mag 2023 a Mag 2024